HCW Biologics Inc. (HCWB) reported a first-quarter net income of $3.47 million on revenue of $6.54 million, reversing a year-earlier loss of $2.20 million. The turnaround was fueled by a licensing agreement with Beijing-based Trimmune Biotech, which provided a much-needed cash infusion for the small Florida-based biotechnology firm.
Despite the positive earnings, HCW Biologics continues to face significant challenges. The company's stock remains below Nasdaq's $1 minimum bid price, threatening its listing status. As of March 31, 2026, cash reserves stood at just $1.23 million, while current liabilities totaled $19.96 million. Management has expressed substantial doubt about the company's ability to continue as a going concern without additional financing.
Licensing Deal Provides Temporary Boost
The licensing agreement with Trimmune Biotech for HCW11-006 generated $3.5 million in gross cash, which translated to $2.9 million after taxes. HCW also received a minority equity stake in Trimmune valued at $3.5 million. According to regulatory filings, the company is eligible for up to $16 million in milestone payments tied to development and regulatory progress, plus royalties, while Trimmune covers development costs in its region.
Autoimmune Pipeline Progress
HCW remains on schedule to deliver preliminary results from the first two dose levels of its Phase 1 trial for HCW9302, targeting alopecia areata, an autoimmune condition that causes hair loss. The company expects to report these initial safety and dosing data in the first half of 2026. Both trial sites are currently enrolling patients, and no dose-limiting toxicities have been reported so far.
CEO Hing C. Wong highlighted HCW9302 as the company's top autoimmune prospect, citing its unique mechanism of action. Unlike existing treatments such as Eli Lilly and Incyte's Olumiant and Pfizer's Litfulo, which are oral kinase inhibitors, HCW9302 targets regulatory T cells to suppress excessive immune activity. However, the drug is still in early-stage development and delivered by injection, facing significant hurdles before it can compete in the crowded alopecia market.
Lung Disease Program Shows Promise
HCW also reported positive animal study results for HCW11-040, a candidate targeting bronchopulmonary dysplasia (BPD), a severe lung disease affecting premature infants. The IND-enabling studies, conducted with Queen's University in Ontario, are a critical step before seeking FDA authorization to begin human trials. The company expects to complete these studies in the second half of 2027, followed by an FDA submission to start clinical trials.
BPD affects approximately 10,000 to 15,000 infants annually in the U.S., with no cure currently available. Wong expressed enthusiasm about the results, stating the company plans to aggressively pursue further development for the condition. The pediatric program could also benefit from the FDA's rare pediatric disease priority review voucher program, which has been extended through September 30, 2029.
Financial Risks and Nasdaq Compliance
Despite the licensing deal, HCW has not generated any revenue from its own immunotherapy products. Since inception, the company has accumulated $102.3 million in net losses. The Nasdaq has yet to rule on whether HCW meets the $1 minimum bid requirement, adding to the uncertainty.
A shareholder vote on warrant proposals tied to Armistice Capital Master Fund is scheduled for the annual meeting on June 15, 2026. The proposals, which were postponed due to a lack of quorum at a special meeting on April 27, involve warrants to purchase up to 5.50 million shares at 60.55 cents each. Armistice Capital has invested $17.4 million in the company.